Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 04 2022 - 4:05PM
Business Wire
- Presentations to be webcast on
www.exelixis.com -
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of
the company’s management team will participate in fireside chats at
the following investor conferences in May:
- BofA Securities 2022 Healthcare Conference: Exelixis is
scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday,
May 11, 2022 in Las Vegas.
- 2022 RBC Capital Markets Global Healthcare Conference: Exelixis
is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday,
May 17, 2022 in New York.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentations to ensure
adequate time for any software download that may be required to
listen to the webcasts. Replays will also be available at the same
location for at least 30 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery – all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of the Standard & Poor’s (S&P) MidCap
400 index, which measures the performance of profitable mid-sized
companies. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX and
COMETRIQ are registered U.S. trademarks of Exelixis. COTELLIC is a
registered trademark of Genentech, Inc. MINNEBRO is a registered
trademark of Daiichi Sankyo Company, Limited.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504005947/en/
Investors Contact: Varant Shirvanian Associate Director,
Investor Relations Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024